Press Releases Ypsomed Group

Burgdorf / Mainz / Basel – Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT, one of the leading suppliers of pharmaceutical primary packaging, and Lonza, a leading global partner of the pharmaceutical and biotechnology industry for the development, manufacturing and testing of pharmaceuticals. In a joint effort, the three companies are developing a comprehensive solution for wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations. This solution should enable pharmaceutical companies to quickly bring biopharmaceuticals in a patch injector into the clinical trial stage and to the market. For patients, the solution reduces the number of hospital visits required for treatment.

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) increased sales by 4.6% or CHF 8.7 million in the first six months of 2020/21 compared to the previous year, and generated an operating profit (EBIT) of CHF 8.3 million. The company continued on its growth course in a challenging environment, driving forward all strategic initiatives and creating 102 new jobs at the same time.

World's first zero carbon emission autoinjector from Ypsomed

Press Releases Ypsomed Group

Burgdorf – Ypsomed has developed the world’s first zero carbon emission prefilled autoinjector. The YpsoMate Zero is based on the proven YpsoMate autoinjector platform that offers convenient handling and patient safety. The new YpsoMate Zero uses alternative biopolymers and a novel packaging design that follows the principles of circular product design.

Ypsomed’s Annual General Meeting approves all proposals and elects Gilbert Achermann as a new member of the Board of Directors

Press Releases Ypsomed Group

Burgdorf – Yesterday, the Annual General Meeting of the Ypsomed Group has approved all proposals and has elected Gilbert Achermann as a new member of the Board of Directors and of the Compensation Committee to succeed Anton Kräuliger. Gilbert Achermann is Chairman of the Board of Directors of the Straumann Group as well as member of the Board of Directors of Vifor Pharma Ltd and Julius Baer Group Ltd.

Ypsomed grows strongly in pharma customer business and continues to invest in the market development of the insulin pump

Press Releases Ypsomed Group

Burgdorf – In the financial year 2019/20, Ypsomed achieved consolidated sales of CHF 393.9 million (previous year: CHF 453.8 million). In the previous year, Ypsomed generated a turnover of 352.8 million in continuing operations. On this comparative basis, the result represents growth of CHF 41.0 million or 11.6 %. The operating result (EBIT) amounts to CHF 9.3 million. In the previous year, the discontinued operation contributed with CHF 61.9 million to the operating result of CHF 73.3 million. Net profit amounts to CHF 11.5 million (previous year: CHF 60.1 million).